Category Medicine and Healthcare

DEA Crushes Illegal Marijuana - But Still Blocks MMJ's Legal Cannabis Drug for Huntington's
Press Release

DEA Crushes Illegal Marijuana - But Still Blocks MMJ's Legal Cannabis Drug for Huntington's

While busting cartels, DEA continues war on science and suffering patients. Duane Boise, CEO of MMJ International Holdings, expressed frustration over the contrasting approaches of federal agencies, stating, "While the FDA is facilitating medical innovation, the DEA's hindrance not only blocks scientific progress but also contradicts directives aimed at revitalizing domestic manufacturing." This situation starkly contrasts with the "Buy American" initiative endorsed by President Trump, which was intended to strengthen U.S. drug production capabilities and reduce dependence on foreign manufacturers.



 

Read More
DEA DIVERSION THE NEW PHARMACEUTICAL ROADBLOCK: Take the case of MMJ's Cannabis Drug Development
Press Release

DEA DIVERSION THE NEW PHARMACEUTICAL ROADBLOCK: Take the case of MMJ's Cannabis Drug Development

The DEA Diversion Control Problem: A Hidden Threat to U.S. Pharmaceutical Manufacturing ?

Take the case of MMJ BioPharma Cultivation - despite submissions of FDA Investigational New Drug (IND) applications and Orphan Drug Designation approval for treating Huntington's Disease - has been blocked from manufacturing cannabis-derived pharmaceuticals by the DEA, under the leadership of Deputy Administrator Thomas Prevoznik.

Read More